Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.65 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.65 |
| ▸ | FABP2 | P12104 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.65 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | DRD3 | P35462 | 1/20 | 0.65 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.65 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30986301 | 1.00 | LMNA (0.65) | LMNAAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL11856480 | 0.87 | AKR1C3 (0.61) | LMNAAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL11804390 | 0.87 | AKR1C3 (0.61) | LMNAAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL8011500 | 0.87 | AKR1C3 (0.60) | LMNAAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL11722780 | 0.87 | PTGS1 (0.49) | LMNAAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL11990042 | 0.87 | AKR1C3 (0.60) | LMNAAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL15564000 | 0.86 | AKR1C3 (0.65) | LMNAAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL11868212 | 0.85 | AKR1C3 (0.63) | LMNAAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL11861696 | 0.84 | LMNA (0.67) | LMNAAKR1C3AKR1C2PTGS1MEN1 | |
| SCHEMBL16909901 | 0.84 | AKR1C3 (0.48) | LMNAAKR1C3AKR1C2PTGS1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4053639-A | 2-(2,2' OR 2,2'-FLUORO OR DIFLUORO-4-BIPHENYLYL)PROPAN-1-OL; ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC | THE BOOTS COMPANY LIMITED (EN) | 1977-10-11 | — | — | US | claimed |
| US-12486218-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20240239739-A1 | COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2024-07-18 | — | — | US | disclosed |
| CN-118344244-A | Preparation method of deuterated compound based on alkyl alcohol | 大连理工大学 | 2024-07-16 | — | — | CN | disclosed |
| US-20210130285-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2021-05-06 | — | — | US | disclosed |
| EP-2268140-B1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA INC (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10793515-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| WO-2017066103-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20160137592-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2016-05-19 | — | — | US | disclosed |
| US-9212155-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9206143-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| WO-2011034849-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMED PHARMA, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110046138-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20110046128-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2268140-A2 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | Aurimmed Pharma, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117515-A2 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-4053639-A | 2-(2,2' OR 2,2'-FLUORO OR DIFLUORO-4-BIPHENYLYL)PROPAN-1-OL; ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC | THE BOOTS COMPANY LIMITED (EN) | 1977-10-11 | — | — | US | disclosed |
| US-4053639-A | 2-(2,2' OR 2,2'-FLUORO OR DIFLUORO-4-BIPHENYLYL)PROPAN-1-OL; ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC | THE BOOTS COMPANY LIMITED (EN) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486218-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | SMN1; SMN2, HDAC6, CTSA | LMNA 680/4885AKR1C3 3261/4885AKR1C2 2559/4885 |
| US-20210130285-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, HDAC3 | LMNA 1000/4885AKR1C3 3295/4885AKR1C2 2552/4885 |
| US-20110046128-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GAP43, CHRNA10, CHRNA6 | LMNA 2068/4885AKR1C3 3672/4885AKR1C2 3176/4885 |
| US-20160137592-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, HDAC3 | LMNA 1000/4885AKR1C3 3295/4885AKR1C2 2552/4885 |
| US-10793515-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | SMN1; SMN2, HDAC6, CTSA | LMNA 680/4885AKR1C3 3261/4885AKR1C2 2559/4885 |
| US-20110046138-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | CHRNA10, CHRNA6, GAP43 | LMNA 2144/4885AKR1C3 4166/4885AKR1C2 3827/4885 |
| US-20240239739-A1 | COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, CTSA | LMNA 680/4885AKR1C3 3261/4885AKR1C2 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.